Higher serum alkaline phosphatase value indicates the need for bone mineral density testing in non-metastatic prostate cancer patients undergoing androgen deprivation therapy.

MLA

Hagiwara, Kanade, et al. “Higher Serum Alkaline Phosphatase Value Indicates the Need for Bone Mineral Density Testing in Non-Metastatic Prostate Cancer Patients Undergoing Androgen Deprivation Therapy.” Japanese Journal of Clinical Oncology, vol. 52, no. 1, Jan. 2022, pp. 73–80. EBSCOhost, https://doi.org/10.1093/jjco/hyab147.

APA

Hagiwara, K., Sakamoto, A., Sasaki, K., Kanatani, A., Kimura, M., Kaneko, T., Takahashi, S., Yamada, Y., & Nakagawa, T. (2022). Higher serum alkaline phosphatase value indicates the need for bone mineral density testing in non-metastatic prostate cancer patients undergoing androgen deprivation therapy. Japanese Journal of Clinical Oncology, 52(1), 73–80. https://doi.org/10.1093/jjco/hyab147

Chicago

Hagiwara, Kanade, Akihiko Sakamoto, Kenichi Sasaki, Atsushi Kanatani, Masaki Kimura, Tomoyuki Kaneko, Sayuri Takahashi, Yukio Yamada, and Tohru Nakagawa. 2022. “Higher Serum Alkaline Phosphatase Value Indicates the Need for Bone Mineral Density Testing in Non-Metastatic Prostate Cancer Patients Undergoing Androgen Deprivation Therapy.” Japanese Journal of Clinical Oncology 52 (1): 73–80. doi:10.1093/jjco/hyab147.